Dapagliflozin (SGLT-2 inhibitor) and sotagliflozin (SGLT1/2 inhibitor) are two 
of the drugs of SGLT inhibitor class which have been recommended by the National 
Institute for Health and Care Excellence (NICE) in people with type 1 diabetes 
with BMI ≥27 kg/m2 . Dapagliflozin is licensed in the UK for use in the NHS 
while sotagliflozin may be available in future. These and possibly other SGLT 
inhibitors may be increasingly used in people with type 1 diabetes as new 
licences are obtained. These drugs have the potential to improve glycaemic 
control in people with type 1 diabetes with the added benefit of weight loss, 
better control of blood pressure and more time in optimal glucose range. 
However, SGLT inhibitors are associated with a higher incidence of diabetic 
ketoacidosis without significant hyperglycaemia. The present ABCD/Diabetes UK 
joint updated position statement is to guide people with type 1 diabetes and 
clinicians using these drugs help mitigate this risk and other potential 
complications. Particularly, caution needs to be exercised in people who are at 
risk of diabetic ketoacidosis due to low calorie diets, illnesses, injuries, 
starvation, excessive exercise, excessive alcohol consumption and reduced 
insulin administration among other precipitating factors for diabetic 
ketoacidosis.